Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Haleon
- License Information
-
More Information
Article History
Received: 3 February 2025
Revised: 4 April 2025
Accepted: 9 April 2025
First Online: 14 April 2025
Declarations
:
: These trials were initiated prior to introduction of clinical trial registries, so trial registration numbers are not available. Both trials were approved by an institutional review board and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation of Good Clinical Practices; all patients gave written informed consent.
: MF: Employee of Haleon.BF: Employee of Haleon.MA: Employee of Haleon.AK: Research Grants: Janssen Pharmaceuticals, Axsome Pharmaceutics, Attune, Eisai, Harmony, Neurocrine Biosciences, Reveal Biosensors, The Ray and Dagmar Dolby Family Fund, Weill Institute for Neurosciences, and the National Institutes of Health.Consulting: Axsome Therapeutics, Abbvie, Big Health, Eisai, Evecxia, Harmony Biosciences, Idorsia, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences, Neumora, Neurawell, Otsuka Pharmaceuticals, Sage, Takeda.Stock Options: Neurawell, Big Health.
